<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifteen American patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated in a clinical trial employing chemotherapy, radiotherapy, and immunotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Two patients died during induction, and 13 achieved complete responses </plain></SENT>
<SENT sid="2" pm="."><plain>Eight patients relapsed at a median of 11 weeks from initial treatment, and seven of these have died </plain></SENT>
<SENT sid="3" pm="."><plain>The remaining patient has enjoyed a prolonged third remission following intensive chemotherapy and bone marrow autograft </plain></SENT>
<SENT sid="4" pm="."><plain>Five patients remain in their first remission in excess of 1 year </plain></SENT>
<SENT sid="5" pm="."><plain>The major therapeutic goal in the management of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is the prevention of relapse; the identification of risk factors and various strategies to achieve this goal are discussed </plain></SENT>
</text></document>